FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

YUEN THOMAS C K
2. Date of Event Requiring Statement (MM/DD/YYYY)
8/10/2021 

3. Issuer Name and Ticker or Trading Symbol

PharmaCyte Biotech, Inc. [PMCB]
(Last)        (First)        (Middle)

23046 AVENIDA DE LA CARLOTA, SUITE 600
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                          _____ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

LAGUNA HILLS, CA 92653      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 1667 (1)D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) 7/3/2017 7/3/2022 Common Stock 334 (1)$87.00 (2)D  
Stock Option (right to buy) 5/1/2018 5/1/2023 Common Stock 334 (1)$80.85 (2)D  
Stock Option (right to buy) 5/1/2019 5/1/2024 Common Stock 334 (1)$60.60 (2)D  
Stock Option (right to buy) 5/1/2020 5/1/2025 Common Stock 334 (1)$36.00 (2)D  
Stock Option (right to buy) 5/1/2021 5/1/2026 Common Stock 334 (1)$26.55 (2)D  

Explanation of Responses:
(1) The number of shares has been adjusted to reflect a one-for-1,500 reverse stock split of the Issuer's common stock effected on July 12, 2021 (the "Reverse Split").
(2) The exercise price has been adjusted to reflect the Reverse Split.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
YUEN THOMAS C K
23046 AVENIDA DE LA CARLOTA
SUITE 600
LAGUNA HILLS, CA 92653
X



Signatures
/s/ Thomas C.K. Yuen8/31/2021
**Signature of Reporting PersonDate

PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more PharmaCyte Biotech Charts.
PharmaCyte Biotech (NASDAQ:PMCB)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more PharmaCyte Biotech Charts.